Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) focus on therapeutics to treat lipid disorders

The share prices of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) had surged by 6.69 percent to close at $62.34 per share for the end of last trading session on Monday. The shares of the company had been trading in the range of $62.01 to $68.60 per during the day, which had pushed the company to hit new peaks. The shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) had a market capitalization of $1.80 billion. The stock opened at $67.34 per share.

Equities research analysts at JP Morgan Cazenove raised their target price on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) to $88.00 in a research note issued to investors on Thursday, JP Morgan Cazenove’s price target indicates a potential upside of 26.67 percent from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase raised their price target on shares of Aegerion Pharmaceuticals to $88.00 in a research note to investors on Wednesday. They noted that the move was a valuation call. Separately, analysts at Bank of America reiterated a “buy” rating on shares of Aegerion Pharmaceuticals in a research note to investors on Friday, June 7th. They now have a $100.00 price target on the stock, up previously from $58.00. Finally, analysts at Jefferies Group raised their price target on shares of Aegerion Pharmaceuticals from $50.00 to $82.00 in a research note to investors on Wednesday, June 5th. They now have a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating; Aegerion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $74.09.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

About the Author

Kevin Goodings financial reporter NYSE post. Authors have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. This article is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. *NYSE Post does not set price targets on securities. Never invest into a stock discussed on this website unless you can afford to lose your entire investment.